{
 "metadata": {
  "name": "",
  "signature": "sha256:8e64bbb5f454ed43bc39f6ce65a91fe81e2026a93d2f38d94b1a19f77b4c6516"
 },
 "nbformat": 3,
 "nbformat_minor": 0,
 "worksheets": [
  {
   "cells": [
    {
     "cell_type": "heading",
     "level": 2,
     "metadata": {},
     "source": [
      "Agreement with EU-ADR for job 716713 when positive and speculative choices are combined"
     ]
    },
    {
     "cell_type": "markdown",
     "metadata": {},
     "source": [
      "2015-04-23 Tong Shu Li"
     ]
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "import pandas as pd\n",
      "import matplotlib.pyplot as plt\n",
      "\n",
      "%matplotlib inline\n",
      "%pylab inline"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Populating the interactive namespace from numpy and matplotlib\n"
       ]
      }
     ],
     "prompt_number": 1
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "from itertools import islice"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 2
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "import sys\n",
      "sys.path.append(\"/home/toby/crowdsourcing/drug_disease_semantics/src/\")\n",
      "\n",
      "from filter_data import filter_data\n",
      "from aggregate_results import aggregate_results\n",
      "from true_relation_type import get_euadr_relation_type\n",
      "from get_orig_problem import get_orig_problem"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 3
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "sys.path.append(\"/home/toby/global_util/\")\n",
      "from file_util import read_file"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 4
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "settings = {\n",
      "    \"loc\": \"/home/toby/crowdsourcing/drug_disease_semantics/data/\",\n",
      "    \"fname\": \"job_716713_full_with_untrusted_and_unfinished.tsv\",\n",
      "    \"data_subset\": \"normal\",\n",
      "    \"min_accuracy\": 0.7,\n",
      "    \"max_accuracy\": 1.0,\n",
      "    \"id_column\": \"pub_rel_id\",\n",
      "    \"categories\": [[\"positive\", \"speculative\"], [\"negative\"], [\"false\"]]\n",
      "}"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 5
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "raw_data = filter_data(settings)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 7
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "euadr_answer = get_euadr_relation_type(settings)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 9
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "len(raw_data)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "metadata": {},
       "output_type": "pyout",
       "prompt_number": 10,
       "text": [
        "1022"
       ]
      }
     ],
     "prompt_number": 10
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def create_match(gold_std_answer):\n",
      "    def match(identifier, crowd_choice):\n",
      "        return int(crowd_choice == gold_std_answer[identifier])\n",
      "    \n",
      "    return match"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 11
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "match_obj = create_match(euadr_answer)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 12
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "results = aggregate_results(\"pub_rel_id\", \"broad_rel_type\", raw_data, match_obj)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 13
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def determine_matches(results):\n",
      "    matches = []\n",
      "    mismatches = []\n",
      "    for rel_id, group in results.groupby(\"pub_rel_id\"):\n",
      "        if group.iloc[0][\"match\"] == 1:\n",
      "            matches.append(rel_id)\n",
      "        else:\n",
      "            mismatches.append(rel_id)\n",
      "            \n",
      "    return (matches, mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 14
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "matches, mismatches = determine_matches(results)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 15
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def broad_reltype_summary(settings):\n",
      "    raw_data = filter_data(settings)\n",
      "\n",
      "    true_relation_type = get_euadr_relation_type(settings)\n",
      "\n",
      "    match_obj = create_match(true_relation_type)\n",
      "\n",
      "    results = aggregate_results(\"pub_rel_id\", \"broad_rel_type\", raw_data, match_obj)\n",
      "\n",
      "#--------------------------------------------------------------------\n",
      "    ans = pd.Series([0] * 4)\n",
      "    for unit_id, group in results.groupby(settings[\"id_column\"]):\n",
      "        temp = list(group[\"match\"])\n",
      "        ans = ans.add(pd.Series(temp), fill_value = 0)\n",
      "\n",
      "    num_work_units = len(results[settings[\"id_column\"]].unique())\n",
      "\n",
      "    print \"Distribution of matches with gold standard based on response rank:\\n{0}\".format(ans)\n",
      "    print\n",
      "    print (\"Total number of work units for this subset of data: {0}\".\n",
      "        format(num_work_units))\n",
      "    print\n",
      "    print \"Number of correct responses with respect to the rank of confidence score:\"\n",
      "    print (\"{0}/{1} ({2}%) work units had the correct answer in the top ranked position\".\n",
      "           format(ans[0], num_work_units, ans[0]/num_work_units * 100))\n",
      "\n",
      "    graph = ans.plot(kind = \"bar\")\n",
      "    graph.set_xlabel(\"Rank of the correct choice according to the crowd\")\n",
      "    graph.set_ylabel(\"Number of work units where the crowd chosen top answer\\n\"\\\n",
      "        \"matched that of the gold standard\")"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 16
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "broad_reltype_summary(settings)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Distribution of matches with gold standard based on response rank:\n",
        "0    173\n",
        "1     19\n",
        "2      2\n",
        "3      0\n",
        "dtype: float64\n",
        "\n",
        "Total number of work units for this subset of data: 244\n",
        "\n",
        "Number of correct responses with respect to the rank of confidence score:\n",
        "173.0/244 (70.9016393443%) work units had the correct answer in the top ranked position\n"
       ]
      },
      {
       "metadata": {},
       "output_type": "display_data",
       "png": "iVBORw0KGgoAAAANSUhEUgAAAY0AAAExCAYAAACAr/7fAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nBwAAAABJRU5ErkJggg==\n",
       "text": [
        "<matplotlib.figure.Figure at 0x7f089610e990>"
       ]
      }
     ],
     "prompt_number": 17
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "orig_problem = get_orig_problem(\"pub_rel_id\", raw_data)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 18
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def sort_by_conf(work_units):\n",
      "    \"\"\"\n",
      "    Sort the work units in decreasing order of agreement\n",
      "    for the top chosen crowd answer.\n",
      "    \"\"\"\n",
      "    temp = []\n",
      "    for rel_id in work_units:\n",
      "        group = results.query(\"pub_rel_id == '{0}'\".format(rel_id))\n",
      "        temp.append((rel_id, group.iloc[0][\"percent_agree\"]))\n",
      "        \n",
      "    temp = sorted(temp, key = lambda x: x[1], reverse = True)\n",
      "    return [val[0] for val in temp]"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 19
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "matches = sort_by_conf(matches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 20
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "mismatches = sort_by_conf(mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 21
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "loc = \"/home/toby/crowdsourcing/drug_disease_semantics/data/\"\n",
      "\n",
      "pub_to_raw_mapping = dict()\n",
      "for line in islice(read_file(loc + \"raw_to_toby_mapping.txt\"), 1, None):\n",
      "    pub_rel_id, raw_rel_id, num_agree = line.split('|')\n",
      "    pub_to_raw_mapping[pub_rel_id] = (raw_rel_id, int(num_agree))"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 23
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def summary(work_units):\n",
      "    for identifier in work_units:\n",
      "        subset = results.query(\"pub_rel_id == '{0}'\".format(identifier))\n",
      "        \n",
      "        unit_id = raw_data.query(\"pub_rel_id == '{0}'\".format(identifier)).iloc[0][\"_unit_id\"]\n",
      "        \n",
      "        print \"Unit id: {0}\".format(unit_id)\n",
      "        print\n",
      "        print \"EU-ADR answer:\", euadr_answer[identifier]\n",
      "        print \"Experts agree: {0}/3\".format(pub_to_raw_mapping[identifier][1])\n",
      "        print\n",
      "        print subset\n",
      "        print\n",
      "        print orig_problem[identifier][3]\n",
      "        print\n",
      "        print \"============================================================\""
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 24
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "summary(mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Unit id: 706124689\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_1  positive_speculative      2.4251          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "[[Cardiovascular thromboembolic adverse effects]] associated with [[cyclooxygenase]]-2 selective inhibitors and nonselective antiinflammatory drugs.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707779908\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_116  positive_speculative        2.85          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "[[Long-term immunomodulatory drug]] (IMD) treatment is now common in [[multiple sclerosis]] (MS).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707780025\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_119       negative      2.5126          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "In ER+ breast tumors, 2.5 mg/d [[tibolone]] given for 14 days has no significant effect on [[tumor]] cell proliferation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124819\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 1/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_121  positive_speculative      2.4848          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Exposure to Benzodiazepines ([[BZD]]) during foetal life has been suggested to contribute to neonatal morbidity and some [[congenital malformations]], for example, orofacial clefts.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124752\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_122  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Exposure to [[Benzodiazepines]] (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, [[orofacial clefts]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124751\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_123  positive_speculative      5.7152          7   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Exposure to [[Benzodiazepines]] (BZD) during foetal life has been suggested to contribute to neonatal morbidity and some [[congenital malformations]], for example, orofacial clefts.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124900\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_124  positive_speculative        2.85          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Maternal use of [[BZD]] and/or HBRA may increase the risk for [[preterm birth]] and low birth weight and cause neonatal symptoms, but does not appear to have a strong teratogenic potential.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706987913"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_125  positive_speculative      2.4833          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Exposure to Benzodiazepines ([[BZD]]) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations, for example, [[orofacial clefts]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124921\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_129  positive_speculative      2.5421          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "After two years [[ecstasy]] users showed persistent [[deficits on verbal fluency]], working memory and processing speed.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124922\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_130  positive_speculative      2.6836          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "When ecstasy users were classified according to lifetime use of [[ecstasy]], the more severe users (more than 100 tablets) showed additional [[deficits on episodic memory]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124800\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_135  positive_speculative      2.5666          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with [[chronic hepatitis C genotype 4]] treated with [[peginterferon]] plus ribavirin.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124691\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_138  positive_speculative      3.2892          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Exposure to [[radioisotopes of metals and halogen elements]] occurring in medical practice may cause [[spontaneous abortions]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124705\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_140  positive_speculative      2.4892          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Women exposed to [[radioisotopes]] experienced at least a threefold higher rate of [[spontaneous abortions]] than those exposed to X-ray (OR = 3.68, 95% CI = 1.39-9.74, P < 0.01).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124743\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_16  positive_speculative       3.416          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Review of recent results of [[montelukast]] use as a monotherapy in children with [[mild asthma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124914\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_162  positive_speculative      2.3596          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "There was an estimated 50% excess risk of [[malignancy]] among [[methotrexate]]-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124866\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_17  positive_speculative      2.5421          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "This article reviewed recent results from randomized, double-blind studies of children with [[mild asthma]] treated with [[montelukast]], a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124903\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_171  positive_speculative      2.4833          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "[[Recombinant hirudin]] is used as an alternative anticoagulant, particularly in patients with [[heparin-induced thrombocytopenia type II]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124725\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_174  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require [[anticoagulant]] medication for prevention of [[thrombosis]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124864\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_182       negative      2.3596          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "This once-weekly regimen is generally well tolerated, and studies to date have reported that [[epoetin beta]] has a neutral effect on survival of patients with [[cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124781\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_183  positive_speculative      3.2578          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "[[Epoetin beta]] once weekly: review of its efficacy and safety in patients with chemotherapy-induced [[anemia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124862\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_199       negative      2.6092          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "Compared with both diuretics and contemporary agents, [[amlodipine]] decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or [[cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124872\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_2  positive_speculative      2.5421          3              1   \n",
        "\n",
        "   match  \n",
        "0      0  \n",
        "\n",
        "[[Cardiovascular thromboembolic adverse effects]] associated with cyclooxygenase-2 selective inhibitors and [[nonselective antiinflammatory drugs]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124808"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_200  positive_speculative      5.7219          7   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "[[Dihydropyridine calcium channel antagonists]] may exert effects that protect against [[stroke]] that are independent of their blood pressure-lowering mechanism.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124826\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_205  positive_speculative       7.415          9   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "[[Dihydropyridine calcium channel antagonists]] have several noteworthy attributes that merit consideration in the management of [[hypertension]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124824\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_219  positive_speculative      2.5873          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "The established [[teratogenicity]] of [[antiepileptic drugs]] raises important issues in women of child-bearing age.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124867\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_227  positive_speculative      2.6836          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Two years after initiating [[SRL]], she presented complaints of progressive dyspnoea, [[nonproductive cough]], chest pain and low-grade fever of 1 month duration.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124718\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_228  positive_speculative      2.4892          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Two years after initiating [[SRL]], she presented complaints of progressive dyspnoea, nonproductive cough, [[chest pain]] and low-grade fever of 1 month duration.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124708\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_229  positive_speculative      2.6209          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "The only patient with [[leucoencephalopathy]] showed improved neurologic status after [[SRL]] conversion.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124896\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_233  positive_speculative        2.85          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), [[gastrointestinal]] (GI) side effects of [[mycophenolate mofetil]] (MMF; n = 5; 15%), and hyperglycemia (n = 4; 12%).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124741\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_237  positive_speculative      2.7424          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Furthermore, the efficacy of the new generation of [[antiepileptic agents]] in the prophylaxis of [[perioperative seizures]] has not been assessed so far.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124790\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_239  positive_speculative      2.4745          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "We tested the hypothesis that oral beclomethasone dipropionate ([[BDP]]) would control [[gastrointestinal graft-versus-host disease]] (GVHD) in patients with anorexia, vomiting, and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707284767\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_54  positive_speculative       2.609          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Past use of [[antimetabolites]], T-cell inhibitors, alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 [[ocular inflammation]] patients at five tertiary centers over up to 30 years.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124898\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_57  positive_speculative      3.3592          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Past use of antimetabolites, T-cell inhibitors, [[alkylating agents]], and other immunosuppressives is ascertained from medical records of approximately 9,250 [[ocular inflammation]] patients at five tertiary centers over up to 30 years.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124920\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_58  positive_speculative      2.6092          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Past use of antimetabolites, [[T-cell inhibitors]], alkylating agents, and other immunosuppressives is ascertained from medical records of approximately 9,250 [[ocular inflammation]] patients at five tertiary centers over up to 30 years.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124690\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_67  positive_speculative      3.5426          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "An inverse trend was observed between dose and multiplicity of [[colonic dysplasias]] in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of dysplasias of the AOM/[[DSS]] controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124834\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_75  positive_speculative      2.5598          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of [[azoxymethane]] (AOM)/dextran sulfate sodium (DSS)-induced [[colitis-associated neoplasia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124711\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_76  positive_speculative      2.7424          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Administration of 75 mg/kg [[5-ASA]] decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of [[polypoid dysplasias]] (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124745\n",
        "\n",
        "EU-ADR answer:"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        " false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_80  positive_speculative      2.6322          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/dextran sulfate sodium ([[DSS]])-induced [[colitis-associated neoplasia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124729\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_86  positive_speculative      4.9747          6   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Recently, there have been reports of [[noninfectious granulomatous syndromes]] in patients receiving [[etanercept]] for a variety of diseases.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124685\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_87  positive_speculative      2.6209          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Development of [[sarcoidosis]] in [[etanercept]]-treated rheumatoid arthritis patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124909\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_88  positive_speculative      2.4148          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Development of sarcoidosis in [[etanercept]]-treated [[rheumatoid arthritis]] patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706988916\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_91  positive_speculative      2.5421          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "[[BiRD]] (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic [[multiple myeloma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124865\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_92  positive_speculative      2.5879          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "This trial determined the safety and efficacy of the combination regimen clarithromycin (Biaxin), lenalidomide (Revlimid), and dexamethasone ([[BiRD]]) as first-line therapy for [[multiple myeloma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124699\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_94  positive_speculative      3.2892          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      0  \n",
        "\n",
        "Recent prospective studies from Europe suggest the use of intracameral [[antibiotics]] for prophylaxis of [[endophthalmitis]], although the studies did not make a comparison with the most common United States prophylaxis techniques.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124810\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_60  positive_speculative      5.0829          6   \n",
        "0  drug_disease_60                 false      0.8333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.859149      0  \n",
        "0       0.140851      1  \n",
        "\n",
        "Information from the SITE Cohort Study should clarify whether use of these [[immunosuppressive drugs]] for [[ocular inflammation]] increases the risk of mortality and fatal cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124838"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_235  positive_speculative      3.4438          4   \n",
        "0  drug_disease_235                 false      0.8000          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1        0.81149      0  \n",
        "0        0.18851      1  \n",
        "\n",
        "Our data showed that oxcarbazepine can be a good alternative to traditional [[antiepileptic agents]] in the prevention of [[perioperative seizures]] being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124746\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_9  positive_speculative      2.7655          3       0.775628   \n",
        "0  drug_disease_9                 false      0.8000          1       0.224372   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  \n",
        "\n",
        "Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with cyclosporin A ([[CsA]])-induced [[gingival overgrowth]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124717\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_132              negative      2.5025          3   \n",
        "1  drug_disease_132  positive_speculative      0.7273          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "0       0.774816      0  \n",
        "1       0.225184      0  \n",
        "\n",
        "No significant differences were observed between FeSO4+citrate and [[NaFe-EDTA]] fortification, regarding mitigation of [[iron-deficiency anemia]] (IDA) or regarding CRP, growth, infections, or side-effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707286745\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_203       negative      2.7947          3       0.770314   \n",
        "0  drug_disease_203          false      0.8333          1       0.229686   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  \n",
        "\n",
        "Compared with both diuretics and contemporary agents, [[amlodipine]] decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease, [[gastrointestinal bleeding]] or cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124754\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_120              negative      2.5509          3   \n",
        "1  drug_disease_120  positive_speculative      0.7692          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "0        0.76832      0  \n",
        "1        0.23168      0  \n",
        "\n",
        "In [[ER+ breast tumors]], 2.5 mg/d [[tibolone]] given for 14 days has no significant effect on tumor cell proliferation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124842\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_143  positive_speculative      2.5901          3   \n",
        "0  drug_disease_143                 false      0.8000          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.764019      0  \n",
        "0       0.235981      1  \n",
        "\n",
        "Primary outcomes were [[asthma exacerbations]] (AE) requiring systemic [[corticosteroids]] or hospitalization, life-threatening exacerbations and asthma-related deaths.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124833\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_89  positive_speculative      2.3743          3   \n",
        "0  drug_disease_89                 false      0.7368          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.763171      0  \n",
        "0       0.236829      1  \n",
        "\n",
        "The other developed [[erythema nodosum]] and a plaque lesion on the right arm after 1 year of [[etanercept]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124788\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_173  positive_speculative      5.5519          7   \n",
        "0  drug_disease_173                 false      0.9412          1   \n",
        "1  drug_disease_173              negative      0.8077          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.760451      0  \n",
        "0       0.128917      1  \n",
        "1       0.110632      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral [[anticoagulant]] and instituting heparin therapy prior to the planned dental procedure, which can result in [[thromboembolism]] and increased morbidity and mortality.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124888\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_134              negative      2.7515          3   \n",
        "1  drug_disease_134  positive_speculative      0.9167          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "0       0.750095      0  \n",
        "1       0.249905      0  \n",
        "\n",
        "No significant differences were observed between [[FeSO4]]+citrate and NaFe-EDTA fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, [[infections]], or side-effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124873\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_198  positive_speculative      2.7189          3   \n",
        "0  drug_disease_198                 false      0.9091          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.749421      0  \n",
        "0       0.250579      1  \n",
        "\n",
        "Long-term exposure to [[medium-dose glucocorticoid]] therapy associates with hypertension in patients with [[rheumatoid arthritis]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124832\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_133              negative      2.4848          3   \n",
        "1  drug_disease_133  positive_speculative      0.8333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "0       0.748862      0  \n",
        "1       0.251138      0  \n",
        "\n",
        "No significant differences were observed between [[FeSO4]]+citrate and NaFe-EDTA fortification, regarding mitigation of [[iron-deficiency anemia]] (IDA) or regarding CRP, growth, infections, or side-effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124818\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_232  positive_speculative      2.2778          3   \n",
        "0  drug_disease_232                 false      0.8333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.732153      0  \n",
        "0       0.267847      1  \n",
        "\n",
        "The reasons for conversion were calcineurin inhibitors (CNI) nephrotoxicity (n = 24; 73%), severe neurotoxicity owing to CNI (n = 1; 3%), severe and/or recurrent acute rejection episodes (n = 7; 21%), [[gastrointestinal]] (GI) side effects of mycophenolate mofetil ([[MMF]]; n = 5; 15%), and hyperglycemia (n = 4; 12%).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124695\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_61  positive_speculative      2.4670          3   \n",
        "0  drug_disease_61                 false      0.9231          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.727707      0  \n",
        "0       0.272293      1  \n",
        "\n",
        "Past use of antimetabolites, T-cell inhibitors, alkylating agents, and other [[immunosuppressives]] is ascertained from medical records of approximately 9,250 [[ocular inflammation]] patients at five tertiary centers over up to 30 years.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124886\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_152              negative      4.2158          5   \n",
        "1  drug_disease_152  positive_speculative      1.6071          2   \n",
        "\n",
        "   percent_agree  match  \n",
        "0       0.724004      0  \n",
        "1       0.275996      1  \n",
        "\n",
        "The study showed that ziprasidone was effective and tolerable, that use of [[ziprasidone]] was characterized by an absence of [[extrapyramidal symptoms]] and weight gain, and that no alterations in clinical laboratory tests occurred.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124905\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_44       negative      2.4148          3       0.718862      0\n",
        "0  drug_disease_44          false      0.9444          1       0.281138      0\n",
        "\n",
        "Interestingly, 5 microM of [[indomethacin-loaded nanocapsules]] was able to cause an antiproliferative effect without promoting necrosis in [[glioma]] cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124703"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_31  positive_speculative      2.3042          3   \n",
        "0  drug_disease_31                 false      0.9286          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.712757      0  \n",
        "0       0.287243      1  \n",
        "\n",
        "The aim of this study was to evaluate the effects of [[indomethacin-loaded nanocapsules]] and indomethacin ethyl ester-loaded nanocapsules on [[glioma]] cell lines.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707131026\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_18          false      4.0003          5       0.711886      0\n",
        "1  drug_disease_18       negative      1.6190          2       0.288114      0\n",
        "\n",
        "A literature search of MEDLINE was conducted to gather relevant, English-language articles using search terms such as randomized controlled studies, double-blind studies, [[montelukast]], leukotriene receptor antagonist, pediatric asthma, [[mild asthma]], exercise-induced asthma, and bronchoconstriction.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124839\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_109                 false      4.6922          6   \n",
        "1  drug_disease_109  positive_speculative      2.6316          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0       0.640678      0  \n",
        "1       0.359322      1  \n",
        "\n",
        "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and [[aspergillosis]] (CI not reported, p < 0.001) when compared with [[fluconazole]] and itraconazole in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124783\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_37  positive_speculative      4.2679          5   \n",
        "0  drug_disease_37                 false      3.1163          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.577977      0  \n",
        "0       0.422023      1  \n",
        "\n",
        "Selective cytotoxicity of indomethacin and [[indomethacin ethyl ester-loaded nanocapsules]] against [[glioma]] cell lines: an in vitro study.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124753\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_131  positive_speculative      4.3622          5   \n",
        "1  drug_disease_131              negative      2.2781          3   \n",
        "0  drug_disease_131                 false      0.9333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.575974      0  \n",
        "1       0.300795      0  \n",
        "0       0.123231      1  \n",
        "\n",
        "No significant differences were observed between FeSO4+citrate and [[NaFe-EDTA]] fortification, regarding mitigation of iron-deficiency anemia (IDA) or regarding CRP, growth, [[infections]], or side-effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124801\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_202              negative      4.2201          5   \n",
        "2  drug_disease_202  positive_speculative      2.5086          3   \n",
        "0  drug_disease_202                 false      0.7333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.565545      0  \n",
        "2       0.336183      0  \n",
        "0       0.098271      1  \n",
        "\n",
        "Compared with both diuretics and contemporary agents, [[amlodipine]] decreases cardiovascular events to a similar or greater extent without evidence for increased [[coronary heart disease]], gastrointestinal bleeding or cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124878\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_66  positive_speculative      4.0681          5   \n",
        "0  drug_disease_66                 false      2.4312          3   \n",
        "1  drug_disease_66              negative      0.8182          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.555941      0  \n",
        "0       0.332245      1  \n",
        "1       0.111814      0  \n",
        "\n",
        "An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg 5-ASA exhibiting 56% of the number of [[dysplasias]] of the AOM/[[DSS]] controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124823\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "1  drug_disease_3       negative      4.1062          5       0.553009      0\n",
        "0  drug_disease_3          false      3.3190          4       0.446991      1"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "The frequency of PONV did not correlate to the amounts of [[alfentanil]], propofol, postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or [[motion sickness]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124813\n",
        "\n",
        "EU-ADR answer: negative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_222  positive_speculative      4.0048          5   \n",
        "1  drug_disease_222              negative      2.5113          3   \n",
        "0  drug_disease_222                 false      0.8077          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.546820      0  \n",
        "1       0.342896      1  \n",
        "0       0.110284      0  \n",
        "\n",
        "Data of our study revealed an unexpected high rate of [[hypogonadism]] irrespective of [[cyclophosphamide]] use, and subclinical involvement of the testes by the vasculitis itself might be an alternative explanation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124749\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_68  positive_speculative      4.1262          5   \n",
        "0  drug_disease_68                 false      3.6420          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.531166      0  \n",
        "0       0.468834      1  \n",
        "\n",
        "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of [[azoxymethane]]/dextran sulfate sodium-induced [[colitis]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124722\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "1  drug_disease_4              negative      3.4528          4       0.452565   \n",
        "0  drug_disease_4                 false      3.3195          4       0.435093   \n",
        "2  drug_disease_4  positive_speculative      0.8571          1       0.112342   \n",
        "\n",
        "   match  \n",
        "1      0  \n",
        "0      1  \n",
        "2      0  \n",
        "\n",
        "The frequency of PONV did not correlate to the amounts of alfentanil, [[propofol]], postoperative antiemetics consumed, or to female gender, non-smoking status, and history of PONV or [[motion sickness]].\n",
        "\n",
        "============================================================\n"
       ]
      }
     ],
     "prompt_number": 25
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "summary(matches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "Unit id: 706124714\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_0  positive_speculative      2.5589          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "Body height, weight and obesity increase the risk of [[venous thrombosis]], especially obesity in women using [[oral contraceptives]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124787\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_101  positive_speculative      2.3788          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The most common adverse effects associated with the use of [[posaconazole]] include headache, fever, [[nausea]], vomiting, and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124869\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_102  positive_speculative      2.5879          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The most common adverse effects associated with the use of [[posaconazole]] include headache, fever, nausea, [[vomiting]], and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124890\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_104  positive_speculative      2.6092          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Similarly, the same regimen of [[posaconazole]] reduced [[invasive fungal infections]] (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124750\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_107  positive_speculative      3.4032          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "At this time, [[posaconazole]] should probably be reserved for prophylaxis in patients at high risk for invasive fungal infection, as salvage therapy in refractory or [[resistant infections]], or for patients with intolerance to other therapies.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124830\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_110  positive_speculative      2.3788          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Posaconazole]], in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and [[aspergillosis]] incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124885\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_112  positive_speculative      2.5879          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Posaconazole is noninferior to [[fluconazole]] for treatment of [[oropharyngeal candidiasis]] (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124821"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_113  positive_speculative      2.4848          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough [[invasive fungal infections]] (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving [[fluconazole]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124917\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_115  positive_speculative      7.3867          9   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "While some beneficial neuromotor effects of succimer therapy were observed in the present study there remains several unanswered questions such as how long these effects will persist and how [[succimer]] therapy modifies lead-associated [[cerebellar deficits]] manifesting as perturbations in vestibular and/or proprioception systems for postural balance and functional locomotion.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706989513\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_117  positive_speculative      3.3022          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "It is well known that [[tobacco smoke]] exposure is related to the risk of developing [[cardiovascular diseases]] and events.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124836\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_118  positive_speculative      2.4745          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Tibolone]] is a selective tissue estrogenic activity regulator, approved for the treatment of [[vasomotor symptoms]] in postmenopausal women.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124687\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_12  positive_speculative      5.0693          6   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "These results suggest that CsA can modulate the expression of ET-1 in gingival fibroblasts and [[CsA]]-induced [[gingival overgrowth]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124702\n",
        "\n",
        "EU-ADR answer: negative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_126       negative       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "We found no evidence of impaired control of the carbohydrate and lipid metabolism or aggravation of [[vascular lesions]] during the two years an [[etonogestrel]] implant was used by diabetic women.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124694\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_127  positive_speculative      6.8545          8   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Oritavancin]]: a new promising agent in the treatment of [[infections due to Gram-positive pathogens]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124772\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_128  positive_speculative      3.2931          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Our findings support that ecstasy use, or [[ecstasy/cannabis]] synergic effects, are responsible for the sub-clinical deficits observed in ecstasy polydrug users, and provides additional evidence for [[long-term cognitive impairment]] owing to ecstasy consumption in the context of polydrug use.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707282367\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_13          false      2.3596          3              1      1\n",
        "\n",
        "Gingival samples were collected from eight normal healthy individuals, eight patients with [[periodontitis]], and eight patients with cyclosporin A ([[CsA]])-induced gingival overgrowth.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124785\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_136  positive_speculative      2.5078          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Adverse events were similar across treatment groups except for higher rates of [[anemia]] in the groups receiving [[ribavirin]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124764\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_137  positive_speculative      2.5078          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Sustained virologic response (SVR) rates of 50%-60% have been achieved in patients with [[chronic hepatitis C genotype 4]] treated with peginterferon plus [[ribavirin]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124877\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_139  positive_speculative      2.4833          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "For exposure levels within standard recommended guidelines, [[radioisotopes]] are far more likely to play a role in the occurrence of [[spontaneous abortions]] than X-rays.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124688\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_14  positive_speculative      2.4221          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Gingival samples were collected from eight normal healthy individuals, eight patients with periodontitis, and eight patients with [[cyclosporin A]] (CsA)-induced [[gingival overgrowth]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124719\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_141  positive_speculative      2.6754          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "An open multicenter phase II trial of weekly [[docetaxel]] for [[advanced-stage non-small-cell lung cancer]] in elderly patients with significant comorbidity and/or poor performance status: The GFPC 02-02b study.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124882\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_142  positive_speculative      2.4148          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Contrarily, [[LABA]] showed a significant increase in [[asthma-related deaths]] (Relative Risk=3.83; 95% CI, 1.21-12.14).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124765"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_144  positive_speculative      2.4245          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of [[high-dose cyclophosphamide]] 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124812\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_145  positive_speculative      2.5873          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, [[adriamycin]] 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124829\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_146  positive_speculative      2.5598          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, [[cisplatin]], cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124820\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_147  positive_speculative      2.5873          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and [[prednisone]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124768\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_15  positive_speculative      5.6485          7   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The evidence suggests that [[montelukast]] is an effective monotherapy controller in children with [[mild asthma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707287260\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_150  positive_speculative        2.85          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of [[etoposide]], cisplatin, cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124740\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_151  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Plasma [[ziprasidone]] levels ranged from 20 ng/mL to 160 ng/mL (mean: 75.8 ng/mL) and were significantly related to the improvement in [[negative symptoms]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124683\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_153  positive_speculative      2.6322          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Characteristic features of an [[inflammation]] induced by [[bevacizumab]] injection include an early onset with painless loss in VA mostly without conjunctival or ciliary injection.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124794\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_154  positive_speculative      2.4745          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/[[prednisone]]) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124919\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_155  positive_speculative      2.5879          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Administration of full-dose R-CHOP ([[rituximab]]/cyclophosphamide/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124759\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_156  positive_speculative      2.6209          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Administration of full-dose R-CHOP (rituximab/cyclophosphamide/[[doxorubicin]]/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124776\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_157  positive_speculative      2.3778          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Administration of full-dose R-CHOP (rituximab/[[cyclophosphamide]]/doxorubicin/vincristine/prednisone) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124786\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_158  positive_speculative      2.6744          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Administration of full-dose R-CHOP (rituximab/cyclophosphamide/doxorubicin/[[vincristine]]/prednisone) chemotherapy is important to maximize response in patients with intermediate-or [[high-grade non-Hodgkin lymphoma]] but might be difficult in older patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124858\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_159  positive_speculative      2.6092          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Compared with the general population, [[methotrexate]]-treated RA patients have an increased incidence of melanoma, non-Hodgkin's lymphoma, and [[lung cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124881\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_160  positive_speculative      2.3596          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Compared with the general population, [[methotrexate]]-treated RA patients have an increased incidence of [[melanoma]], non-Hodgkin's lymphoma, and lung cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707218352\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_161  positive_speculative      2.5421          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Compared with the general population, [[methotrexate]]-treated RA patients have an increased incidence of melanoma, [[non-Hodgkin's lymphoma]], and lung cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124795\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_163  positive_speculative      2.5873          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "There was an estimated 50% excess risk of malignancy among [[methotrexate]]-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in [[non-Hodgkin's lymphoma]] (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124835\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_165  positive_speculative      2.5078          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "There was an estimated 50% excess risk of malignancy among [[methotrexate]]-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in [[melanoma]] (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in lung cancer (SIR 2.9, 95% CI 1.6-4.8).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124852\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_166  positive_speculative      2.5598          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Incidence of melanoma and other malignancies among [[rheumatoid arthritis]] patients treated with [[methotrexate]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124894\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_167  positive_speculative      2.6836          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "To determine cancer risk in a cohort of 459 [[rheumatoid arthritis]] (RA) patients treated with [[methotrexate]] in community practice.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124912\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_168  positive_speculative      2.4148          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "To determine [[cancer]] risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with [[methotrexate]] in community practice.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124828\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_169  positive_speculative      2.5666          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Incidence of melanoma and other [[malignancies]] among rheumatoid arthritis patients treated with [[methotrexate]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124721\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_170  positive_speculative      2.4892          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Incidence of [[melanoma]] and other malignancies among rheumatoid arthritis patients treated with [[methotrexate]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124803"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_172  positive_speculative      2.5666          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Absence of villin predisposes mice to [[dextran sodium sulfate]]-induced [[colitis]] by promoting apoptosis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124727\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_176  positive_speculative      2.4221          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Finally, in non-small cell lung cancer (NSCLC) in patients' progressing on chemotherapy [[sutent]] was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for [[lung cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124793\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_177  positive_speculative      2.5078          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "In several phase I/II/III studies, [[sutent]] was found to be effective as second and first line treatment in [[metastatic renal cell carcinoma]] (RCC).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124911\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_178  positive_speculative      2.5879          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Finally, in non-small cell lung cancer ([[NSCLC]]) in patients' progressing on chemotherapy [[sutent]] was able to achieve a 10% response rate, a level of activity similar to those documented by other agents approved for lung cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124763\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_179  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Sutent]] was also effective as second line treatment in patients with gastrointestinal stromal tumors ([[GIST]]) with 8% response rate, 70% stable disease and a 20-month median survival.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124737\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_180  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "In addition, a phase II study in multitreated women with [[breast cancer]], [[sutent]] demonstrated a moderate activity with 16% clinical benefit.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124739\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_181  positive_speculative      2.6039          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Epoetin beta]] effectively increases hemoglobin levels, reduces the need for transfusions and improves the quality of life in patients with symptomatic chemotherapy-induced [[anemia]] with a range of solid tumors and lymphoid malignancies.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124761\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_184  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "During the induction phase, tacrolimus or cyclosporine, [[mycophenolate mofetil]], and methylprednisolone were used for [[immunosuppression]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124907"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_185  positive_speculative       2.609          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "During the induction phase, [[tacrolimus]] or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for [[immunosuppression]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124902\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_186  positive_speculative      2.5879          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and [[methylprednisolone]] were used for [[immunosuppression]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124758\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_187  positive_speculative      2.7424          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "During the induction phase, tacrolimus or [[cyclosporine]], mycophenolate mofetil, and methylprednisolone were used for [[immunosuppression]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124797\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_188  positive_speculative      2.5598          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The most frequent and the most troublesome adverse effect of [[interferon]] plus ribavirin-based therapy is [[anaemia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124709\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_189  positive_speculative      2.4892          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "In multivariate analysis the risk of [[anaemia]] was significantly associated with [[zidovudine]] (OR, 3.27 95% CI, 1.64-6.54, P = 0.0008) and peg-IFN (OR, 2.35; 95% CI, 1.16-4.57, P = 0.0179).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707284912\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_19  positive_speculative      2.4833          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The results from these studies, encompassing end points measuring lung function and symptoms, found that [[montelukast]] provided effective and beneficial [[asthma]] control to children aged 2 to 14 years with mild asthma.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124680\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_190  positive_speculative      6.2663          7   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Zidovudine]] discontinuation could help to avoid [[anaemia]] associated with anti-HCV therapy.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124742\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_191  positive_speculative      3.3201          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "The risk of [[anaemia]] was lower in patients with higher baseline haemoglobin levels (OR, 0.35 95% CI, 0.26-0.49, P < 0.0001) and in patients receiving [[protease inhibitor]]-based antiretroviral therapy (OR, 0.51 95% CI, 0.30-0.86, P = 0.0114).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124716\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_192  positive_speculative      2.4221          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The most frequent and the most troublesome adverse effect of interferon plus [[ribavirin]]-based therapy is [[anaemia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124732\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_193  positive_speculative      2.4004          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "This study demonstrated that both low-dose topiramate and [[propranolol]] could significantly reduce [[migraine headache]] frequency, intensity, and duration.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707280277\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_194  positive_speculative      2.5879          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "This study demonstrated that both low-dose [[topiramate]] and propranolol could significantly reduce [[migraine headache]] frequency, intensity, and duration.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124825\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_197  positive_speculative      2.5666          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Long-term exposure to [[medium-dose glucocorticoid]] therapy associates with [[hypertension]] in patients with rheumatoid arthritis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124883\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_20  positive_speculative      2.6092          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "This article reviewed recent results from randomized, double-blind studies of children with mild asthma treated with [[montelukast]], a leukotriene receptor antagonist that is approved for the treatment of asthma and [[allergic rhinitis]] in children and adults.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124796\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_201  positive_speculative      3.2931          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Collectively, the cardiovascular benefit, metabolic neutrality and homogeneous blood pressure response illuminated in recent studies, and reviewed here, represent a reaffirmation of the benefit of [[long-acting dihydropyridine calcium channel antagonists]] and should serve to help reinforce the critical importance of these agents in the therapeutic armamentarium against [[cardiovascular disease]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124844\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_204  positive_speculative      3.4821          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Compared with both diuretics and contemporary agents, [[amlodipine]] decreases [[cardiovascular events]] to a similar or greater extent without evidence for increased coronary heart disease, gastrointestinal bleeding or cancer.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124678\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_206  positive_speculative      4.1178          5   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "All three patients had recurrent admissions for stomal bleeding and [[stomal varices secondary to portal hypertension]] and were initially treated with local measures (pressure, [[silver nitrate]], and suture ligation).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124774\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_207  positive_speculative      2.4867          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "All three patients had recurrent admissions for [[stomal bleeding]] and stomal varices secondary to portal hypertension and were initially treated with local measures (pressure, [[silver nitrate]], and suture ligation).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124863\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_209  positive_speculative      2.5879          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did [[allopurinol]] (300 or 100 mg) or placebo in subjects with [[hyperuricemia]] and gout, including those with mild to moderately impaired renal function.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124811\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_21  positive_speculative      2.3788          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The combination of high-dose MTX with [[procarbazine]] and CCNU is feasible and effective and results in a low rate of [[leukoencephalopathy]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124748\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_210  positive_speculative      2.5845          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "A significantly (P < 0.05) higher percentage of subjects with [[impaired renal function]] treated with [[febuxostat]] 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of allopurinol (0 [0%] of 10).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124831\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_211  positive_speculative      3.3181          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The primary reasons for withdrawal were similar across groups except for [[gout flares]], which were more frequent with febuxostat than with [[allopurinol]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124730\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_212  positive_speculative      2.4221          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "At all doses studied, [[febuxostat]] more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and [[gout]], including those with mild to moderately impaired renal function.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124856\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_213  positive_speculative      2.4148          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "At all doses studied, [[febuxostat]] more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with hyperuricemia and gout, including those with mild to moderately [[impaired renal function]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124789\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_214  positive_speculative      2.5598          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "At all doses studied, [[febuxostat]] more effectively lowered and maintained serum urate levels <6.0 mg/dl than did allopurinol (300 or 100 mg) or placebo in subjects with [[hyperuricemia]] and gout, including those with mild to moderately impaired renal function.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124815\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_216  positive_speculative      2.5078          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The primary reasons for withdrawal were similar across groups except for [[gout flares]], which were more frequent with [[febuxostat]] than with allopurinol.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124906\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_217  positive_speculative      2.4833          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although diarrhea and [[dizziness]] were more frequent in the [[febuxostat]] 240 mg group.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124814\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_218  positive_speculative      2.5078          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Proportions of subjects experiencing any adverse event or serious adverse event were similar across groups, although [[diarrhea]] and dizziness were more frequent in the [[febuxostat]] 240 mg group.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706694486\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_22  positive_speculative      2.4148          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The combination of [[high-dose MTX]] with procarbazine and CCNU is feasible and effective and results in a low rate of [[leukoencephalopathy]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124728\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_220  positive_speculative      2.4221          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "While the association between [[neural tube defects]] and [[antiepileptic drugs]] is well recognised, other congenital malformations are known to occur.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124871\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_224  positive_speculative        2.85          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The patient was on corticosteroids and [[azathioprine]] for [[autoimmune hepatitis]] at the time of her presentation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124734\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_225  positive_speculative      2.5589          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Pulmonary alveolar proteinosis]]: a rare pulmonary toxicity of [[sirolimus]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707276727"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_226  positive_speculative      2.4148          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[PAP]] is a very rare complication of [[SRL]] therapy with only a few cases described.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124837\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_23  positive_speculative      2.3778          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The combination of high-dose MTX with procarbazine and [[CCNU]] is feasible and effective and results in a low rate of [[leukoencephalopathy]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707283394\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_230  positive_speculative      2.4148          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "All patients converted to SRL because of [[GI side effects]] of [[MMF]] showed improvements, and none of those converted because of hyperglycemia experienced improvement.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124879\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_231  positive_speculative      2.4833          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "We concluded that conversion to SRL in pancreas transplantation should be considered an important alternative strategy, particularly for CNI nephrotoxicity and neurotoxicity, and in cases of [[severe diarrhea]] due to [[MMF]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124779\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_236  positive_speculative      2.5598          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Our data showed that [[oxcarbazepine]] can be a good alternative to traditional antiepileptic agents in the prevention of [[perioperative seizures]] being efficacy, ease of use (rapid titration in 3 days, not requiring close plasma concentration monitoring) and good tolerability (no major side effects during titration and during the first postoperative week) the key factors.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124784\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_238  positive_speculative      2.4745          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "We tested the hypothesis that [[oral beclomethasone dipropionate]] (BDP) would control gastrointestinal graft-versus-host disease ([[GVHD]]) in patients with anorexia, vomiting, and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124895\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_240  positive_speculative       2.609          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Oral BDP prevents [[relapses of gastrointestinal GVHD]] following tapering of [[prednisone]]; survival is statistically significantly better among patients receiving BDP.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124840\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_241  positive_speculative      2.4848          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Oral BDP prevents [[relapses of gastrointestinal GVHD]] following tapering of prednisone; survival is statistically significantly better among patients receiving [[BDP]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124736"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_242  positive_speculative      2.4004          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Grade 3 or 4 leukopenia and [[edema]] and various grade 1 or 2 adverse events were more frequent in patients receiving eight [[TAC]] cycles than in those receiving six cycles.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124697\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_243  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Grade 3 or 4 [[leukopenia]] and edema and various grade 1 or 2 adverse events were more frequent in patients receiving eight [[TAC]] cycles than in those receiving six cycles.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124874\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_25  positive_speculative      2.6092          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same [[pain]] relief as [[intravenous meperidine]] and diazepam.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124798\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_27  positive_speculative      2.3788          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Intra-articular injection of lidocaine before closed reduction of [[anterior shoulder dislocation]] produces the same pain relief as intravenous meperidine and [[diazepam]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124870\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_28  positive_speculative       2.609          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Intra-articular injection of lidocaine before closed reduction of [[anterior shoulder dislocation]] produces the same pain relief as [[intravenous meperidine]] and diazepam.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124698\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_30  positive_speculative      2.4686          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Intra-articular injection of lidocaine]] before closed reduction of anterior shoulder dislocation produces the same [[pain]] relief as intravenous meperidine and diazepam.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124910\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_32  positive_speculative      2.6836          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of [[indomethacin-loaded nanocapsules]] or indomethacin ethyl ester-loaded nanocapsules, in [[glioma]] cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124706\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_33  positive_speculative      7.3413          9   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Selective cytotoxicity of [[indomethacin]] and indomethacin ethyl ester-loaded nanocapsules against [[glioma]] cell lines: an in vitro study.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124735\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_34  positive_speculative      2.7424          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The main finding of the present study is that [[indomethacin-loaded nanocapsules]] formulation was more potent than a solution of indomethacin in decreasing the viability and cell proliferation of [[glioma]] lines.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124713\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_35  positive_speculative      3.3312          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The main finding of the present study is that indomethacin-loaded nanocapsules formulation was more potent than a [[solution of indomethacin]] in decreasing the viability and cell proliferation of [[glioma]] lines.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124889\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_36  positive_speculative      2.6836          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "In addition, when the [[glioma]] cells were exposed to 25 microM of indomethacin-loaded nanocapsules or [[indomethacin ethyl ester-loaded nanocapsules]], a necrotic cell death was observed.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124806\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_38  positive_speculative      2.4245          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "In addition, when the [[glioma]] cells were exposed to 25 microM of [[indomethacin-loaded nanocapsules]] or indomethacin ethyl ester-loaded nanocapsules, a necrotic cell death was observed.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124876\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_41  positive_speculative      2.4833          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The aim of this study was to evaluate the effects of indomethacin-loaded nanocapsules and [[indomethacin ethyl ester-loaded nanocapsules]] on [[glioma]] cell lines.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124733\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_42  positive_speculative      2.4892          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Indomethacin and [[indomethacin ethyl ester]] associated together in the same nanocapsule formulation caused a synergic effect decreasing [[glioma]] cell proliferation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124884\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_43  positive_speculative      2.3596          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Indomethacin]] and indomethacin ethyl ester associated together in the same nanocapsule formulation caused a synergic effect decreasing [[glioma]] cell proliferation.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124853\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_47  positive_speculative      2.3778          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "We describe a patient with acute lymphocytic leukemia (ALL) who developed [[visceral varicella-zoster virus]] (VZV) infection following cord blood stem cell transplantation (CBSCT) and was successfully treated with [[intravenous acyclovir]] (ACV).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124807\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_48  positive_speculative      2.5078          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "We describe a patient with acute lymphocytic leukemia (ALL) who developed visceral varicella-zoster virus ([[VZV) infection]] following cord blood stem cell transplantation (CBSCT) and was successfully treated with [[intravenous acyclovir]] (ACV).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124693\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_49  positive_speculative      7.5666          9   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Available studies in the literature using clozapine in the pediatric population are summarized and the NIMH experience in treating [[refractory childhood-onset schizophrenia]] cases with [[clozapine]] is discussed.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124704\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_5  positive_speculative       2.397          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "However, decreased tear production after [[botulinum toxin]] injection for crow's feet is a possible complication and patients should be advised of the small but definite risk of a temporary [[dry eye]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124707\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_50  positive_speculative      2.4004          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Although the role of [[clozapine]] is well established for [[treatment-resistant schizophrenia]], it is rarely used in pediatric populations, mainly due to its potentially serious adverse effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124893\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_51  positive_speculative      2.3596          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "To summarize practical aspects of use of [[clozapine]] in treating children with [[schizophrenia]] and management of associated adverse effects.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124747\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_52  positive_speculative      3.4655          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Despite a higher incidence of adverse effects in children, [[clozapine]] appears to be a uniquely beneficial second-line agent for treating children with [[refractory schizophrenia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124854\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_53  positive_speculative      2.5598          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Keratoacanthoma]] occurring within the [[red dye of a tattoo]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707285195"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_55  positive_speculative      2.6836          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Information from the SITE Cohort Study should clarify whether use of these [[immunosuppressive drugs]] for ocular inflammation increases the risk of mortality and [[fatal cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124696\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_56  positive_speculative      2.7424          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Calculated detectable differences for mortality/[[fatal malignancy]] with respect to the general population are 22%/49% for [[antimetabolites]], 28%/62% for T-cell inhibitors, and 36%/81% for alkylating agents.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124682\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_59  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Calculated detectable differences for mortality/[[fatal malignancy]] with respect to the general population are 22%/49% for antimetabolites, 28%/62% for [[T-cell inhibitors]], and 36%/81% for alkylating agents.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124908\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_6  positive_speculative        2.85          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "[[Botulinum toxins]] are potent neurotoxins used in a variety of [[neurological disorders]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124899\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_63  positive_speculative      2.3596          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "There were consistent significant [[miosis]] in the right eyes with instilled [[Garcinia kola nut extract]] compared to the left eyes at 15, 30 and 45 minutes (p=0.0000).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707283605\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_69  positive_speculative       2.609          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[5-aminosalicylic acid]] inhibits [[colitis-associated colorectal dysplasias]] in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124892\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_7  positive_speculative      2.6836          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "We describe the case of a 10-year-old boy who developed systemic weakness following treatment of [[spasticity]] with [[botulinum toxin type B]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124802\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_70  positive_speculative      2.4245          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane (AOM)/[[dextran sulfate sodium]] (DSS)-induced [[colitis-associated neoplasia]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707283108\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_71  positive_speculative      2.4833          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "These data suggest that [[low-dose 5-ASA]] may be efficacious in preventing [[colitis-associated dysplasias]] and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with ulcerative colitis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124904\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_72  positive_speculative      7.5923          9   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "These data suggest that [[low-dose 5-ASA]] may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of [[colonic neoplasms]] in patients with ulcerative colitis.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707278758\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_74  positive_speculative       2.609          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The impact of the antiinflammatory agent 5-aminosalicylic acid ([[5-ASA]]) on the risk for [[colitis-associated colorectal cancer]] remains controversial.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124843\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_77  positive_speculative      2.3034          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Administration of 75 mg/kg [[5-ASA]] decreased both the mean multiplicity of flat dysplasias (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias ([[tumor]] burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124738\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_79  positive_speculative      2.7424          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Administration of 75 mg/kg [[5-ASA]] decreased both the mean multiplicity of [[flat dysplasias]] (1.8 +/- 0.4 for drug-treated versus 5.6 +/- 1.2 for AOM/DSS control) and the burden of polypoid dysplasias (tumor burden: 6.7 +/- 2.7 for drug-treated versus 14.9 +/- 3.9 units for AOM/DSS controls) significantly (P = 0.002 and 0.04, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707287494\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "       pub_rel_id        broad_rel_type  conf_score  num_votes  percent_agree  \\\n",
        "0  drug_disease_8  positive_speculative      2.3596          3              1   \n",
        "\n",
        "   match  \n",
        "0      1  \n",
        "\n",
        "We describe the case of a 10-year-old boy who developed [[systemic weakness]] following treatment of spasticity with [[botulinum toxin type B]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124915\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_81  positive_speculative      2.6092          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "An inverse trend was observed between dose and multiplicity of [[colonic dysplasias]] in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg [[5-ASA]] exhibiting 56% of the number of dysplasias of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124822"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_82  positive_speculative      2.3788          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Spinal cord infarction]] secondary to [[cocaine]] use.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124849\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_83  positive_speculative      2.5983          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Cocaine]] abuse is associated with [[cerebrovascular events]]; spinal cord effects are rarely reported.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124731\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_84  positive_speculative       2.397          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Although uncommon, [[cocaine]] abuse can cause [[spinal cord infarction]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707004997\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_85  positive_speculative      2.5421          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "We report two rheumatoid arthritis patients developing [[sarcoidosis]] possibly induced by [[etanercept]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124861\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_90  positive_speculative      2.3596          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "Furthermore, there may be a relationship between [[statin]] dose and [[cancer]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124891\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_93  positive_speculative       2.609          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[BiRD]] is an effective regimen with manageable side effects in the treatment of symptomatic, newly diagnosed [[multiple myeloma]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 707286886\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_96  positive_speculative      2.5126          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "In this study, a 2-year-old girl with [[nephropathic cystinosis]] and severe gastrointestinal dysmotility was treated with intravenous ([[i.v.) administration of cysteamine hydrochloride]] (HCl).\n",
        "\n",
        "============================================================\n",
        "Unit id: 707283447\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_97  positive_speculative        2.85          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "The most common adverse effects associated with the use of [[posaconazole]] include headache, fever, nausea, vomiting, and [[diarrhea]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124817"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "0  drug_disease_98  positive_speculative      2.4564          3   \n",
        "\n",
        "   percent_agree  match  \n",
        "0              1      1  \n",
        "\n",
        "[[Posaconazole]] is noninferior to fluconazole for treatment of [[oropharyngeal candidiasis]] (95% CI -6.6 to 5.0), but necessity for this indication remains unclear, as many other treatment options exist.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124875\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_106  positive_speculative      6.6010          8   \n",
        "0  drug_disease_106              negative      0.7857          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.893633      1  \n",
        "0       0.106367      0  \n",
        "\n",
        "At this time, [[posaconazole]] should probably be reserved for prophylaxis in patients at high risk for [[invasive fungal infection]], as salvage therapy in refractory or resistant infections, or for patients with intolerance to other therapies.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124850\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_95  positive_speculative       6.615          8   \n",
        "0  drug_disease_95                 false       0.800          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.892111      1  \n",
        "0       0.107889      0  \n",
        "\n",
        "A multipronged approach to limit [[endophthalmitis]] risk is also needed, with [[antibiotics]] as only part of the strategy.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124724\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_40  positive_speculative      6.6163          8   \n",
        "0  drug_disease_40                 false      0.8235          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.889312      1  \n",
        "0       0.110688      0  \n",
        "\n",
        "Further investigations using in vivo [[glioma]] model should be helpful to confirm the distinct effects of indomethacin-loaded nanocapsules and [[indomethacin ethyl ester-loaded nanocapsules]], in normal versus tumoral cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124868\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_45  positive_speculative      6.3885          8   \n",
        "0  drug_disease_45              negative      0.8182          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.886467      1  \n",
        "0       0.113533      0  \n",
        "\n",
        "Further investigations using in vivo [[glioma]] model should be helpful to confirm the distinct effects of [[indomethacin-loaded nanocapsules]] and indomethacin ethyl ester-loaded nanocapsules, in normal versus tumoral cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124715\n",
        "\n",
        "EU-ADR answer: false\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id broad_rel_type  conf_score  num_votes  percent_agree  match\n",
        "0  drug_disease_10          false      4.2055          5       0.845378      1\n",
        "1  drug_disease_10       negative      0.7692          1       0.154622      0\n",
        "\n",
        "ET-1 mRNA expression was significantly higher in patients with [[CsA]]-induced gingival overgrowth (P <0.001) than in patients with [[periodontitis]] and the controls.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124770\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_149  positive_speculative      4.1183          5   \n",
        "0  drug_disease_149                 false      0.8182          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.834255      1  \n",
        "0       0.165745      0  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, vincristine and prednisone alternating with three courses of etoposide, cisplatin, [[cytarabine]] and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124816\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_175  positive_speculative      3.3668          4   \n",
        "0  drug_disease_175                 false      0.8000          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.808006      1  \n",
        "0       0.191994      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral anticoagulant and instituting [[heparin]] therapy prior to the planned dental procedure, which can result in [[thromboembolism]] and increased morbidity and mortality.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124767\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_221  positive_speculative      6.0411          7   \n",
        "0  drug_disease_221                 false      1.6182          2   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.788727      1  \n",
        "0       0.211273      0  \n",
        "\n",
        "While the association between neural tube defects and [[antiepileptic drugs]] is well recognised, other [[congenital malformations]] are known to occur.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124762\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_73  positive_speculative      6.0452          7   \n",
        "0  drug_disease_73                 false      0.9231          1   \n",
        "1  drug_disease_73              negative      0.7692          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.781286      1  \n",
        "0       0.119302      0  \n",
        "1       0.099412      0  \n",
        "\n",
        "These data suggest that [[low-dose 5-ASA]] may be efficacious in preventing colitis-associated dysplasias and provide strong support for optimizing this therapy for the prevention of colonic neoplasms in patients with [[ulcerative colitis]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124773\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_46  positive_speculative      2.5245          3   \n",
        "0  drug_disease_46                 false      0.7333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.774909      1  \n",
        "0       0.225091      0  \n",
        "\n",
        "Quantification of circulating varicella-zoster virus DNA for follow-up in a case of [[visceral varicella-zoster infection]] ameliorated with [[intravenous acyclovir]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124780\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_78  positive_speculative      2.5245          3   \n",
        "0  drug_disease_78                 false      0.7333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.774909      1  \n",
        "0       0.225091      0  \n",
        "\n",
        "An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups (P = 0.03), with animals receiving 75 mg/kg [[5-ASA]] exhibiting 56% of the number of [[dysplasias]] of the AOM/DSS controls (mean +/- SEM: 7.6 +/- 1.4 and 13.6 +/- 2.7, respectively).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124775\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_111  positive_speculative      2.5901          3   \n",
        "0  drug_disease_111                 false      0.8000          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.764019      1  \n",
        "0       0.235981      0  \n",
        "\n",
        "[[Posaconazole]], in doses of 200 mg 3 times daily, reduced breakthrough [[invasive fungal infections]] (OR 0.30; 95% CI 0.12 to 0.71) and aspergillosis incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving fluconazole.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124804\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_24  positive_speculative      2.5901          3   \n",
        "0  drug_disease_24                 false      0.8000          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.764019      1  \n",
        "0       0.235981      0  \n",
        "\n",
        "[[Intra-articular injection of lidocaine]] before closed reduction of [[anterior shoulder dislocation]] produces the same pain relief as intravenous meperidine and diazepam.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124916\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_195  positive_speculative      2.5483          3   \n",
        "0  drug_disease_195                 false      0.8077          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.759327      1  \n",
        "0       0.240673      0  \n",
        "\n",
        "Results - The [[topiramate]] group showed a reduction in the mean (+/-SD) of monthly migraine frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, [[headache]] intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124757"
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_164  positive_speculative      2.5971          3   \n",
        "0  drug_disease_164                 false      0.8333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.757084      1  \n",
        "0       0.242916      0  \n",
        "\n",
        "There was an estimated 50% excess risk of malignancy among [[methotrexate]]-exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2-1.9), with a 3-fold increase in melanoma (SIR 3.0, 95% CI 1.2-6.2), a 5-fold increase in non-Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2-10.0), and an almost 3-fold increase in [[lung cancer]] (SIR 2.9, 95% CI 1.6-4.8).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124726\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_29  positive_speculative      2.5971          3   \n",
        "0  drug_disease_29                 false      0.8333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.757084      1  \n",
        "0       0.242916      0  \n",
        "\n",
        "Mean [[pain]] (mm) recorded before injection, before reduction, and after reduction in the [[intra-articular lidocaine]] group was 84.3 (95% confidence interval (CI) 79.8 to 88.8), 52.6 (95% CI 45.2 to 60.1), and 27.3 (95% CI 19.9 to 34.7), respectively.\n",
        "\n",
        "============================================================\n",
        "Unit id: 707780960\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_234  positive_speculative      2.8611          3   \n",
        "0  drug_disease_234              negative      0.9333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.754032      1  \n",
        "0       0.245968      0  \n",
        "\n",
        "Moreover, [[oxcarbazepine]] can be a valid choice when long-term therapy is required because of the low interaction with other drugs and the low [[hematological side effects]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706985414\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_105  positive_speculative      2.4421          3   \n",
        "0  drug_disease_105              negative      0.8333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.745588      1  \n",
        "0       0.254412      0  \n",
        "\n",
        "The most common adverse effects associated with the use of [[posaconazole]] include [[headache]], fever, nausea, vomiting, and diarrhea.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124848\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_103  positive_speculative      4.3053          5   \n",
        "0  drug_disease_103                 false      0.8462          1   \n",
        "1  drug_disease_103              negative      0.7333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.731597      1  \n",
        "0       0.143794      0  \n",
        "1       0.124609      0  \n",
        "\n",
        "Similarly, the same regimen of [[posaconazole]] reduced invasive fungal infections (95% CI -9.7 to -2.5) and [[aspergillosis]] (CI not reported, p < 0.001) when compared with fluconazole and itraconazole in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124846\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_26  positive_speculative      1.7594          2   \n",
        "0  drug_disease_26                 false      0.7273          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.707524      1  \n",
        "0       0.292476      0  \n",
        "\n",
        "Intra-articular injection of lidocaine before closed reduction of anterior shoulder dislocation produces the same [[pain]] relief as intravenous meperidine and [[diazepam]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124710\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_196  positive_speculative      1.8517          2   \n",
        "0  drug_disease_196              negative      0.7692          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.706513      1  \n",
        "0       0.293487      0  \n",
        "\n",
        "Results - The [[topiramate]] group showed a reduction in the mean (+/-SD) of monthly [[migraine]] frequency from 6.07 (+/-1.89) to 1.83 (+/-1.39) episodes per month, headache intensity from 7.1 (+/-1.45) to 3.67 (+/-2.1) based on the Visual Analog Scale, and headache duration from 16.37 (+/-7.26) to 6.23 (+/-5.22) hours (P < 0.001).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124756\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_11  positive_speculative      1.9091          2   \n",
        "0  drug_disease_11              negative      0.8333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.696142      1  \n",
        "0       0.303858      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "ET-1 mRNA expression was significantly higher in patients with [[CsA]]-induced [[gingival overgrowth]] (P <0.001) than in patients with periodontitis and the controls.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124723\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_215  positive_speculative      5.2462          6   \n",
        "1  drug_disease_215              negative      1.5549          2   \n",
        "0  drug_disease_215                 false      0.8000          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.690190      1  \n",
        "1       0.204562      0  \n",
        "0       0.105248      0  \n",
        "\n",
        "A significantly (P < 0.05) higher percentage of subjects with [[impaired renal function]] treated with febuxostat 80 mg (4 [44%] of 9), 120 mg (5 [45%] of 11), and 240 mg (3 [60%] of 5) achieved the primary end point compared with those treated with 100 mg of [[allopurinol]] (0 [0%] of 10).\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124686\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_108  positive_speculative      5.3364          6   \n",
        "0  drug_disease_108                 false      1.7091          2   \n",
        "1  drug_disease_108              negative      0.7692          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.682867      1  \n",
        "0       0.218703      0  \n",
        "1       0.098430      0  \n",
        "\n",
        "Similarly, the same regimen of posaconazole reduced [[invasive fungal infections]] (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with [[fluconazole]] and itraconazole in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124855\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_208  positive_speculative      4.9656          6   \n",
        "0  drug_disease_208                 false      1.6333          2   \n",
        "1  drug_disease_208              negative      0.7333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.677232      1  \n",
        "0       0.222757      0  \n",
        "1       0.100011      0  \n",
        "\n",
        "At all doses studied, febuxostat more effectively lowered and maintained serum urate levels <6.0 mg/dl than did [[allopurinol]] (300 or 100 mg) or placebo in subjects with hyperuricemia and [[gout]], including those with mild to moderately impaired renal function.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124744\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_148  positive_speculative      5.2119          6   \n",
        "0  drug_disease_148                 false      1.7564          2   \n",
        "1  drug_disease_148              negative      0.7692          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.673590      1  \n",
        "0       0.226998      0  \n",
        "1       0.099412      0  \n",
        "\n",
        "Forty-one patients [30 males and 11 females, median age 47 years] consecutively diagnosed with [[PTCL]] received three courses of high-dose cyclophosphamide 2000 mg/m(2)/day, adriamycin 90 mg/m(2)/day, [[vincristine]] and prednisone alternating with three courses of etoposide, cisplatin, cytarabine and prednisone.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124681\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_99  positive_speculative      4.4928          5   \n",
        "0  drug_disease_99                 false      1.6278          2   \n",
        "1  drug_disease_99              negative      1.5025          2   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.589367      1  \n",
        "0       0.213535      0  \n",
        "1       0.197098      0  \n",
        "\n",
        "Similarly, the same regimen of posaconazole reduced invasive fungal infections (95% CI -9.7 to -2.5) and [[aspergillosis]] (CI not reported, p < 0.001) when compared with fluconazole and [[itraconazole]] in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124841\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_62  positive_speculative      4.3012          5   \n",
        "0  drug_disease_62                 false      3.1240          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.579271      1  \n",
        "0       0.420729      0  \n",
        "\n",
        "Calculated detectable differences for mortality/[[fatal malignancy]] with respect to the general population are 22%/49% for antimetabolites, 28%/62% for T-cell inhibitors, and 36%/81% for [[alkylating agents]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124805\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_100  positive_speculative      4.3753          5   \n",
        "0  drug_disease_100                 false      1.7333          2   \n",
        "1  drug_disease_100              negative      1.5025          2   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.574858      1  \n",
        "0       0.227733      0  \n",
        "1       0.197409      0  "
       ]
      },
      {
       "output_type": "stream",
       "stream": "stdout",
       "text": [
        "\n",
        "\n",
        "Similarly, the same regimen of posaconazole reduced [[invasive fungal infections]] (95% CI -9.7 to -2.5) and aspergillosis (CI not reported, p < 0.001) when compared with fluconazole and [[itraconazole]] in neutropenic patients.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124679\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "1  drug_disease_114  positive_speculative      4.6257          5   \n",
        "0  drug_disease_114                 false      3.4956          4   \n",
        "\n",
        "   percent_agree  match  \n",
        "1       0.569576      1  \n",
        "0       0.430424      0  \n",
        "\n",
        "Posaconazole, in doses of 200 mg 3 times daily, reduced breakthrough invasive fungal infections (OR 0.30; 95% CI 0.12 to 0.71) and [[aspergillosis]] incidence (OR 0.31; 95% CI 0.13 to 0.75) in patients receiving hematopoietic stem-cell transplants compared with those receiving [[fluconazole]].\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124771\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_39  positive_speculative      4.1544          5   \n",
        "1  drug_disease_39              negative      2.5743          3   \n",
        "0  drug_disease_39                 false      0.7333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.556741      1  \n",
        "1       0.344988      0  \n",
        "0       0.098271      0  \n",
        "\n",
        "Another important finding was that the cytotoxic effect induced by 25 microM or 50 microM of indomethacin-loaded nanocapsules or [[indomethacin ethyl ester-loaded nanocapsules]], in [[glioma]] cells was not observed in the organotypic cultures, indicating selective cytotoxicity of those formulations for tumoral cells.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124684\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_65  positive_speculative      4.2677          5   \n",
        "1  drug_disease_65              negative      2.5999          3   \n",
        "0  drug_disease_65                 false      0.8000          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.556589      1  \n",
        "1       0.339076      0  \n",
        "0       0.104335      0  \n",
        "\n",
        "There is evidence in the literature that [[inhaled corticosteroids]] (ICSs) are safe for pregnant women with [[asthma]] and their infants.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124782\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 3/3\n",
        "\n",
        "        pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_64  positive_speculative      4.1098          5   \n",
        "0  drug_disease_64                 false      2.4619          3   \n",
        "1  drug_disease_64              negative      0.8125          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.556567      1  \n",
        "0       0.333401      0  \n",
        "1       0.110032      0  \n",
        "\n",
        "There is evidence in the literature that inhaled corticosteroids ([[ICSs]]) are safe for pregnant women with [[asthma]] and their infants.\n",
        "\n",
        "============================================================\n",
        "Unit id: 706124712\n",
        "\n",
        "EU-ADR answer: positive_speculative\n",
        "Experts agree: 2/3\n",
        "\n",
        "         pub_rel_id        broad_rel_type  conf_score  num_votes  \\\n",
        "2  drug_disease_223  positive_speculative      3.3201          4   \n",
        "0  drug_disease_223                 false      3.2879          4   \n",
        "1  drug_disease_223              negative      0.7333          1   \n",
        "\n",
        "   percent_agree  match  \n",
        "2       0.452250      1  \n",
        "0       0.447863      0  \n",
        "1       0.099887      0  \n",
        "\n",
        "Data of our study revealed an unexpected high rate of hypogonadism irrespective of [[cyclophosphamide]] use, and subclinical involvement of the testes by the [[vasculitis]] itself might be an alternative explanation.\n",
        "\n",
        "============================================================\n"
       ]
      }
     ],
     "prompt_number": 26
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "def graph_confidence(work_units):\n",
      "    conf = []\n",
      "    \n",
      "    for rel_id in work_units:\n",
      "        group = results.query(\"pub_rel_id == '{0}'\".format(rel_id))\n",
      "        \n",
      "        conf.append(group.iloc[0][\"percent_agree\"])\n",
      "        \n",
      "    graph = pd.Series(sorted(conf, reverse = True)).plot()\n",
      "    \n",
      "    graph.set_ylim((0, 1.1))"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [],
     "prompt_number": 27
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "graph_confidence(matches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "metadata": {},
       "output_type": "display_data",
       "png": "iVBORw0KGgoAAAANSUhEUgAAAW8AAAD7CAYAAAClvBX1AAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nkQak4S0i0oA0vEVEGtD/A1BMfweJT8pUAAAAAElFTkSuQmCC\n",
       "text": [
        "<matplotlib.figure.Figure at 0x7f08960b6d90>"
       ]
      }
     ],
     "prompt_number": 28
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "graph_confidence(mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "metadata": {},
       "output_type": "display_data",
       "png": "iVBORw0KGgoAAAANSUhEUgAAAXUAAAD7CAYAAACVMATUAAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nDXURkRLRUBcRKZH/B0gzRAZAEzWtAAAAAElFTkSuQmCC\n",
       "text": [
        "<matplotlib.figure.Figure at 0x7f0896108b90>"
       ]
      }
     ],
     "prompt_number": 29
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [
      "graph_confidence(matches + mismatches)"
     ],
     "language": "python",
     "metadata": {},
     "outputs": [
      {
       "metadata": {},
       "output_type": "display_data",
       "png": "iVBORw0KGgoAAAANSUhEUgAAAW8AAAD7CAYAAAClvBX1AAAABHNCSVQICAgIfAhkiAAAAAlwSFlz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\nBAAAAABJRU5ErkJggg==\n",
       "text": [
        "<matplotlib.figure.Figure at 0x7f0895fc9b90>"
       ]
      }
     ],
     "prompt_number": 30
    },
    {
     "cell_type": "code",
     "collapsed": false,
     "input": [],
     "language": "python",
     "metadata": {},
     "outputs": []
    }
   ],
   "metadata": {}
  }
 ]
}